NSAIDs are a diverse group of medications used to treat patients with acute and chronic pain as well as to reduce inflammation.
1 x 1 McCarberg, B. and Gibofsky, A. Need to develop new nonsteroidal anti-inflammatory drug formulations. Clin Ther. 2012; 34: 1954–1963 Abstract | Full Text | Full Text PDF | PubMed | Scopus (20) | Google Scholar See all References Although NSAIDs are commonly prescribed due to their proven efficacy in treating pain, they often present safety and tolerability issues, including serious concerns related to gastrointestinal (GI), cardiovascular (CV), and renal toxicity. Traditional, nonselective NSAIDs such as diclofenac have been associated with GI events and in particular upper GI bleeding/perforation (UGIB).
2 x 2 Wolfe, M.M., Lichtenstein, D.R., and Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340: 1888–1899 Crossref | PubMed | Scopus (1732) | Google Scholar See all References Efforts have been taken to mediate NSAID toxicity, including use of proton pump inhibitors for their gastroprotective effects, development of cyclooxygenase-2 (COX-2) selective inhibitors, and development of topical NSAIDs. Newer, COX-2–selective NSAIDs were developed in part for the potential to reduce the risk of GI events but have subsequently demonstrated an increased risk of CV events. In particular, rofecoxib, a COX-2–selective inhibitor, was removed from the market in late 2004 when a clinical study demonstrated that the drug was associated with increased rates of CV events in patients with colorectal polyps.
3 x 3 Bresalier, R.S., Sandler, R.S., Quan, H...., and for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092–1102 Crossref | PubMed | Scopus (2031) | Google Scholar See all References Subsequently, efforts focused on understanding whether the risks observed with rofecoxib were also present for other COX-2–selective inhibitors and for nonselective NSAIDs.